A single center experience in preemptive kidney transplantation.
Transplantation is recognized as preemptive if it takes place before the initiation of chronic dialysis. This maneuver has the potential to avoid the morbidity and burden of chronic dialysis. From November 2003 to April 2005, 15 (7 male, 8 female) end-stage renal failure patients of mean age 40 +/- 14.8 years received preemptive grafts from 2 living-related and 13 cadaveric donors, constituting 11.5% of all kidney transplantations performed in our center at that time. The period on the waiting list for preemptive recipients, namely, 2 weeks to 6 months (mean, 2.4 months), was significantly shorter than that of other patients (mean, 13.8 months). The mean creatinine clearance calculated from the Cockroft Gault formula and the mean plasma creatinine level in preemptive recipients before transplantation were 12.7 +/- 3.1 mL/min and 6.6 +/- 0.8 mg/dL, respectively. The donors for preemptive and non-preemptive groups of recipients did not differ significantly in respect to age, gender, and renal function. The mean number of mismatches of 3.73 and 3.25 and the mean total ischemic times of 9.53 +/- 5 and 11.2 +/- 5 hours, in preemptive and non-preemptive groups of recipients, respectively. The incidence of delayed graft function (dialysis in the first week after transplantation) was significantly lower among preemptive recipients (20% versus 42%, respectively). The groups did not differ either in respect to the occurrence of acute rejection episodes or graft and patient survivals. In preemptive patients the mean plasma creatinine levels at 3 and 12 months were 1.37 +/- 0.3 and 1.09 +/- 0.3 mg/dL, and in non-preemptive patients 1.7 +/- 0.5 and 1.4 +/- 0.4 mg/dL. In conclusion, these results are promising, confirming the notion that preemptive kidney transplantation is the optimal treatment for end-stage renal disease patients.
Debska-Slizień
A
A
Departments of Nephrology, Transplantology and Internal Diseases, Gdańsk Medical University, ul. Debinki 7, 80-211 Gdańsk, Poland. adeb@amg.gda.pl
Wołyniec
W
W
Chamienia
A
A
Wojnarowski
K
K
Milecka
A
A
Zadrozny
D
D
Pirski
I
I
Moszkowska
G
G
Sledziński
Z
Z
Rutkowski
B
B
D000328:Adult; D003404:Creatinine / Q000097:blood; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011044:Poland; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data; D016896:Treatment Outcome
D003404:Creatinine